Quantcast

Sustained Release Ocular Drug Delivery Systems

July 3, 2014

DUBLIN, July 3, 2014 /PRNewswire/ – Research and Markets (http://www.researchandmarkets.com/research/78d22b/sustained_release) has announced the addition of the “Sustained Release Ocular Drug Delivery Systems” report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Given the intricacy of the anatomy and physiology of the eye, it is quite challenging to deliver an ophthalmic drug effectively to a specific ocular site.



Several barriers have to be overcome for successful ocular drug delivery. For example, dilution of a drug by tears, clearance of a drug by the lymphatic system of conjunctiva, drug permeation issues with respect to the cornea, sclera, choroid etc. Accordingly, different drug delivery systems have been devised for controlled release of drugs to various parts of the eye.



Intravitreal implants for delivery of drugs to the posterior segment of the eye are already commercially available. Moreover, a number of companies are developing injectable particulate systems for controlled drug delivery to treat such diseases. This has been the primary focus for sustained delivery of drugs till date. However, industry and academia are working on novel implants, including drug-eluting contact lenses and punctal plugs, for treatment of anterior segment diseases such as glaucoma and conjunctivitis.



The Sustained Release Ocular Drug Delivery Systems, 2014 – 2024′ report provides an extensive study of the emerging market of implants and particulate drug delivery systems (DDS) for ophthalmic diseases. The focus of this study is on commercial implants and those under development, their applications and the likely mid-term and long-term evolution. It is widely anticipated that the ophthalmic drug delivery systems market has tremendous potential. The sustained drug delivery systems provide improved retention time compared to topical applications and offer convenience over regular intravitreal injections, mainly for posterior eye diseases.



The report covers various aspects such as technological progress, product pipeline, industry and academic research programs to assess new evolving opportunities.



One of the key objectives of this report is to understand the current and future state of the ophthalmic sustained drug delivery market. This is done by analysing the following:

    --  Ophthalmic sustained release drug delivery systems currently available
        in the market
    --  Ophthalmic sustained release drug delivery systems currently in the
        pipeline
    --  Leading technology providers and drug delivery systems developers
    --  Most commonly targeted indications and drugs being delivered

    --  Size of target consumer segments

The base year for the report is 2013. The report provides market forecasts for the following two time horizons: 2014 – 2019 and 2019 – 2024, respectively. We have discussed, in detail, key drivers behind the likely growth of ophthalmic drug delivery systems market. The research, analysis and insights presented in this report include the sales potential of various marketed and late stage pipeline ocular sustained drug delivery system products based on the current expected launch timelines, adoption rates and the estimated end-use price points. The figures mentioned in this report are in USD, unless otherwise specified.



Key Topics Covered:



1. Preface



2. Executive Summary



3. Introduction



4. Market Overview



5. Product Profiles And Sales Forecast



6. Company Profiles



7. SWOT Analysis



8. Interview Transcripts



9. Conclusion



10. Appendix 1: Tabulated Data



11. Appendix 2: List of Companies and Organizations



For more information visit http://www.researchandmarkets.com/research/78d22b/sustained_release



Media Contact:
Laura Wood, +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets


Source: PR Newswire



comments powered by Disqus